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At a Glance: Quantification of CT parenchymal patterns in idiopathic pulmonary 
fibrosis using computer tools has been suggested as a method that can improve on 
mortality prediction using visual CT scoring. As computer technology advances, it has 
now become possible to study CT parenchymal features that have no visual 
correlate.  Our study demonstrates that computer-derived vessel-related structure 
scores can outperform current gold-standard measures of outcome in idiopathic 
pulmonary fibrosis such as forced vital capacity decline. Specifically, we demonstrate 
that using thresholds of computer-derived vessel-related structure scores for cohort 
enrichment can identify idiopathic pulmonary fibrosis patients that respond to 
antifibrotic medication with reduced FVC decline and improved survival. 
Importantly, the vessel-related structure thresholds would be able to reduce 
idiopathic pulmonary fibrosis drug-trial population sizes by 26% thereby dramatically 
reducing study costs. 
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Abstract: Aims: To determine whether computer-derived computed tomography 
measures, specifically measures of pulmonary vessel-related structures, can better 
predict functional decline and survival in idiopathic pulmonary fibrosis (IPF) and 
reduce requisite sample sizes in drug trial populations. 
Methods: IPF patients undergoing volumetric non-contrast CT imaging at the Royal 
Brompton Hospital, London and St Antonius Hospital, Utrecht, were examined to 
identify pulmonary functional measures (including forced vital capacity), and visual 
and computer-derived (CALIPER) CT features predictive of mortality and forced vital 
capacity decline. The discovery cohort constituted 247 consecutive patients with 
validation of results in a separate cohort of 284 patients all fulfilling drug trial entry 
criteria. 
Results: In discovery and validation cohorts, CALIPER-derived features, particularly 
vessel-related structure (VRS) scores were amongst the strongest predictors of 
survival and forced vital capacity decline. CALIPER results were accentuated in 
patients with less extensive disease, outperforming pulmonary function measures. 
When used as a cohort enrichment tool, a CALIPER VRS score >4.4% of the lung was 
able to reduce the requisite sample size of an IPF drug trial by 26%. 
Conclusions: Our study has validated a new quantitative CT measure in IPF patients 
fulfilling drug trial entry criteria, the VRS scores, that outperformed current gold-
standard measures of outcome. When used for cohort enrichment in an IPF drug-
trial setting, VRS threshold scores can reduce a required IPF drug trial population size 
by 25%, thereby limiting prohibitive trial costs. Importantly VRS scores identify 
patients in whom antifibrotic medication prolongs life and reduces forced vital 
capacity decline.    
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ABBREVIATIONS 
ILD   Interstitial lung disease 
CT   Computed tomography 
PFT  Pulmonary function test 
FEV1   Forced expiratory volume in one second 
FVC  Forced vital capacity 
DLco   Diffusing capacity for carbon monoxide 
Kco   Carbon monoxide transfer coefficient 
CPI   Composite physiologic index 
GAP   Gender, age physiology 
CALIPER  Computer-Aided Lung Informatics for Pathology Evaluation and 
Rating 
HR   Hazard ratio 
CI   Confidence interval 
TxBx   Traction bronchiectasis 
IPF   Idiopathic pulmonary fibrosis 
CILD  CALIPER interstitial lung disease extent 
CFibrosis CALIPER fibrosis extent 
CVRS  CALIPER vessel-related structure 
CHC  CALIPER honeycombing extent 
UZ  Upper zone 
MZ  Middle zone 
LZ  Lower zone 
UZVRS  Upper zone vessel-related structure 
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MZVRS  Middle zone vessel-related structure 
LZVRS  Lower zone vessel-related structure 
VILD  Visual interstitial lung disease extent 
VFibrosis Visual fibrosis extent 
VHC  Visual honeycombing extent 
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INTRODUCTION 
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing lung disease of 
increasing prevalence(1-5) that results in a patient’s median survival being curtailed 
to only 3-5 years from diagnosis(1, 6-11). In a drug trial setting, a decline in forced 
vital capacity (FVC) has been used as the primary measure of outcome in IPF(12-17), 
and has been correlated with survival in several IPF cohorts(13, 15, 18-21). FVC 
testing is associated with a degree of measurement variation(22), and evidence from 
several clinical studies(15, 18-20, 23) confirms that a 10% FVC decline threshold is a 
surrogate marker of mortality, and in the absence of an alternative explanation, an 
indicator of genuine disease progression(11). 
 
Given the inexorable decline associated with late-stage IPF, characterisation of 
indicators suggesting a poor prognosis at baseline in IPF is essential to guide optimal 
management and allow timely referral for lung transplantation(24). In IPF drug trial 
settings, cohort enrichment strategies aim to create more homogenous study 
populations and identify patients that are likely to experience increased clinical 
events(25) thereby reducing sample sizes and lessening the prohibitive costs 
associated with clinical trials(26). 
 
Given the rapid recent advances in computer technology, the focus of imaging based 
disease biomarkers in IPF has primarily fallen on computer analysis of CT imaging 
which is without the constraints of interobserver variation associated with visual CT 
scoring. New computer algorithms utilising three-dimensional volumetric CT 
datasets, can quantify parenchymal pattern extents(27, 28) and have been shown to 
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better predict survival in various fibrosing lung diseases at baseline, than visual CT 
scores(29, 30). Computer analysis also has the potential to uncover CT features 
hitherto under-recognised by visual CT analysis that predict mortality in IPF. The 
quantitation of pulmonary vessels (arteries and veins) and vessel-related structures 
(perivascular fibrosis)[Figure 1], which cannot be achieved by the human eye, have 
been shown to associate strongly with survival in a series of IPF patients(29).  
 
However, the utility of quantitation of vessel-related structures (VRS) in predicting 
survival in IPF has not been examined across multicentred patient cohorts, and in 
patients with less extensive disease. It also remains unclear whether computer 
analysis of CT imaging can identify patients at risk of progressive disease and in turn 
act as a cohort enrichment tool in IPF. Our study therefore evaluated mortality 
prediction using pulmonary function tests (PFTs), composite indices and visual and 
computer-based CT scoring in a discovery cohort of IPF patients of varying disease 
severity. Prediction of decline in FVC using baseline measures, as well as a combined 
endpoint of a 10% relative FVC decline or death within 12 months was also 
investigated. Statistically significant variables from these analyses were then 
examined in a separate IPF validation cohort. We also examined whether specific 
thresholds of computer-derived CT variables, particularly VRS measures, could be 
used to enrich drug trial eligible IPF populations. 
 
Materials and Methods 
Study Design 
 10 
All research subjects were diagnosed with IPF by a multidisciplinary team and had 
received a non-contrast volumetric CT scan as part of their clinical care. In this 
observational study, all consecutive IPF patients presenting to the Royal Brompton 
Hospital between January 2007 and June 2011 were included in the discovery 
cohort. All IPF patients presenting between July 2011 to December 2014 to the Royal 
Brompton Hospital and IPF patients presenting to the St Antonius Hospital were 
amalgamated to form the validation dataset.  
 
Pulmonary function test, echocardiography and CT protocols are outlined in the 
Supplementary appendix. CALIPER CT analysis has been previously described(29, 31), 
and is outlined in the Supplementary appendix.  
 
CT pattern evaluation 
CT variables scored visually and by CALIPER included honeycombing, reticular 
pattern and ground glass opacity extents. Fibrosis extent represented the sum of 
reticular and honeycombing extents. Interstitial lung disease (ILD)extent additionally 
summed ground-glass opacification. Visual scores also quantified traction 
bronchiectasis extent and severity. CALIPER also quantified pulmonary VRS (details 
in Supplementary appendix). Volumes for all CALIPER parenchymal features were 
converted into a percentage using the total lung volume measured by CALIPER. The 
pulmonary VRS score was subdivided according to cross-sectional area and zonal 
location of the structures (described below). The VRS subdivisions were expressed as 
a percentage of the three CALIPER-derived zonal volumes. 
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Statistical Analysis 
We compared the association of the five PFT scores (FVC, DLco, CPI, GAP score and 
GAP index), five visual CT scores (ILD extent, fibrosis extent, honeycombing extent, 
traction bronchiectasis severity and extent), four CALIPER CT parenchymal scores 
(ILD extent, fibrosis extent, honeycombing and CALIPER total VRS) and 18 detailed 
VRS variables (the five different cross-sectional areas [<5mm2, 5-10 mm2, 10-15 
mm2, 15-20 mm2, >20 mm2] occurring in either the upper, middle or lower zones of 
the lungs, and the three total zonal VRS scores) resulting in 32 predictors in total. We 
considered different measures of clinical outcome, i.e., death or longitudinal FVC 
trajectories. Each predictor variable was tested alone while correcting for 
confounders. Adjustment was made for covariates to demonstrate the additional 
benefit of CALIPER variables when compared to more routinely acquired clinical and 
functional variables.  
 
In our primary analyses, to compare the predictor variables, the -log10 p-values for 
each measure from the discovery and validation sets were plotted on the x- and y-
axes, respectively, labelling the axes using the p-value scale, and including both 
horizontal and vertical lines marking the Li and Ji corrected cutoff for statistical 
significance(32). The Bonferroni method is a conservative method for multiple 
testing correction: the significance threshold (alpha=0.05) is divided by the number 
of conducted tests (usually equivalent to the number of tested variables). 
Bonferroni, however, assumes that all tests are statistically independent. In practice 
however, this assumption is often violated because of strong correlations between 
tested variables. This includes the analysis presented here (e.g., CAL VRS and UZ VRS 
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are strongly correlated R2=0.77). We therefore used the method by Li and Ji in order 
to estimate the effective number of independent tests (Meff), which is derived from 
the eigenvalues of the correlation matrix of all tested variables. We then used Meff 
in order to adjust the significance threshold: alpha=0.05/Meff. Essentially the 
method by Li and Ji allows calculation of the number of effective independent tests, 
and then a Bonferroni correction is applied to that number instead of being applied 
indiscriminately to all variables. 
 
Longitudinal analysis 
A subset of subjects in both cohorts was followed longitudinally with repeated 
pulmonary function tests. Percent change from baseline FVC (raw) was modelled 
using linear mixed effects with random intercept and random slope. More precisely, 
each follow-up FVC value was divided by the baseline FVC value and multiplied by 
100 (FVC%). FVC% was the target variable and confounders were baseline raw FVC, 
sex, age at CT image, smoking status (ever vs. never) and time since baseline FVC as 
well as interactions between time and sex, age, and smoking status. As an additional 
confounder, we used the predictor variable and then measured the effect of the 
predictor-by-time interaction as a means on how the predictor affects the 
longitudinal percentage decline in FVC. The lmer function from the R package 
lme4(33) was used for the analysis. We present the –log10 p-values of the predictor-
by-time interaction for discovery and validation cohort.  
 
In addition to the linear mixed effects analysis, we calculated, for each subject the 
presence or absence of a 10% decline in FVC at twelve months. More precisely, for 
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each subject we estimated a 10% FVC loss within 12 months based on best linear 
unbiased predictions (BLUPs) from the longitudinal mixed model (a minimum of four 
months of follow-up data was required). The presence of a 10% FVC decline at 
twelve months was defined based on the fitted trajectory, i.e., the predicted value at 
twelve months was 10 percent lower than the baseline FVC measurement.  
 
We combined the endpoint of a 10% FVC decline at twelve months with a second 
endpoint of death within twelve months and using logistic regression, considered 
both endpoints as the outcome variable. One logistic regression was fitted per 
predictor and the models were corrected for sex, age at CT imaging and smoking 
status (ever vs. never). The glm function in R was used for this analysis. As above we 
present the –log10 p-values of the predictor for discovery and validation cohorts. 
 
Survival analysis 
We performed a survival analysis using right-censored Cox proportional hazards 
models. Time to event (death) or censoring was measured from CT imaging. The 
models were corrected for sex, age at CT imaging and smoking status (ever vs. 
never). The analysis was conducted using the coxph function of the survival 
package(34) in R(35). As above we present the –log10 p-values of the predictor for 
discovery and validation cohorts.  
 
We also calculated the C-index(36) in the discovery cohort based on 500 bootstrap 
replicates for the logistic regression (10% FVC decline/death within 12 months) and 
Cox mortality models. We further computed C-indices in the validation cohort by 
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applying models with regression coefficients for the variable of interest and 
confounders estimated in the discovery cohort. We also calculated the improvement 
in the model C-index when a powerful VRS measure was added to a model adjusted 
for confounders, and containing either FVC, DLco or CPI. 
 
Drug trial power calculation 
We conducted a power analysis to explore possible sample size reductions in clinical 
trials using CVRS as an enrichment parameter. The power analysis was based on a 
two-sample t-test with p-value threshold of 0.05 and assuming 90% power. Further, 
we assumed that the control group in an IPF drug trial would be receiving antifibrotic 
medication rather than a placebo and would on average decline by 120 mls/year in 
FVC. The rate of decline in FVC in the control arm is therefore an average of rates of 
FVC decline in the treated arms of anti-fibrotic trials12,13. 
 
Three different drug effects were investigated: 25%, 40% and 50% effect leading to 
annual average decline in FVC of 90 ml, 72 ml and 60 ml, respectively. In order to 
derive the effect size (Cohen's d), we computed the standard deviation in the cohort 
with DLco≥30. We used the stable estimator for standard deviation based on median 
absolute deviation (MAD), resulting in 230.27. Thus, in the unenriched design, the 
effect sizes (d) are 0.13, 0.21 and 0.26, respectively. For the enrichment design, we 
considered CVRS thresholds that retain 70%, 50% and 30% of subjects with 
DLco≥30% predicted: 3.7, 4.4, and 5.1. Again, we used the stable estimator to 
compute the standard deviation of annual FVC decline in these enriched subgroups: 
228.1, 197.4 and 195.6. These values were used to derive the corresponding effect 
 15 
size that would be seen when considering the potency of each drug and the 
corresponding sample sizes for a trial. In published anti-fibrotic studies where these 
data are available(16, 37), standard deviations of FVC decline graphed or derived 
from graphed standard errors, did not differ materially between treatment and non-
treatment arms. 
 
The C-index was calculated for the logistic regression and mortality models that 
contained the CVRS thresholds in both the discovery and validation cohorts where 
patients fulfilled drug trial entry criteria (DLco≥30% predicted). We finally also 
examined the effect on study outcome measures from antifibrotic use in drug trial 
eligible patients selected for cohort enrichment.   
 
RESULTS 
Baseline data 
To evaluate the potential of computer-derived indices to aid cohort enrichment in a 
drug-trial setting, our cardinal analyses considered IPF patients fulfilling drug trial 
inclusion criteria(17). Accordingly, patients with a percent-predicted DLco between 
30-90% were analysed in the discovery (n=163) and validation cohort (n=200). Two 
secondary analyses were also performed. Firstly, after combining the discovery and 
validation cohorts, we separately examined patients with a DLco≥30% predicted who 
were not exposed to antifibrotic medication (n=200), and those that had received 
antifibrotics (n=159), to characterise the effects of medication on CT measures 
predicting FVC decline and survival. Antifibrotic use was categorised on an intention 
to treat basis. Secondly, we examined patients with a DLco<30% predicted in both 
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discovery (n=84) and validation cohorts (n=84) to evaluate the performance of 
computer tools in predicting the various study outcome measures in patients with 
severe disease. 
 
Patients with a DLco≥30% predicted in the validation cohort had a marginally higher 
mean DLco than patients in the discovery cohort with no statistically significant 
difference identified in other baseline variables (Supplementary Table 1). No 
statistically significant difference in survival curves was found between cohorts 
(Supplementary Figure 1a and b). 
 
FVC decline 
Across the entire discovery (n=181) and validation (n=207) cohorts, CALIPER 
variables (particularly upper zone VRS and CALIPER fibrosis extent) were the 
strongest predictors of FVC decline (Figure 2A). When analyses were limited to 
patients in the discovery (n=130) and validation (n=168) cohorts with a DLco≥30% 
predicted, upper and midzone VRS subdivisions and visual traction bronchiectasis 
extent were more powerful than functional indices and visual ILD and fibrosis 
extents in predicting FVC decline (Figure 2D).  
 
10% FVC decline/death at 12 months 
When all patients in the discovery (n=224) and validation (n=251) cohorts were 
evaluated, CALIPER VRS variables (particularly total VRS and upper and midzone VRS 
subdivisions) were the strongest predictors of the combined endpoint, 
outperforming all functional indices (Figure 2B). In patients with a DLco≥30% 
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predicted across the discovery (n=148) and validation (n=176) cohorts, UZ VRS 
subdivisions, and visual traction bronchiectasis severity and extent were the most 
powerful predictors of the combined endpoint, though no single variable satisfied 
both Li and Ji cutoffs for statistical significance (Figure 2E).  
 
Survival analyses 
When all study patients were examined in the discovery (n=247) and validation 
(n=284) cohorts, DLco and CPI were the most powerful predictors of survival. Total 
VRS and UZ VRS also strongly predicted survival across both cohorts (Figure 2C). In 
patients fulfilling drug trial entry criteria (DLco≥30% predicted)[n=363], functional 
indices (CPI and DLco), total and UZ VRS and large VRS (>20mm) in the middle and 
upper zones best predicted survival (Figure 2F).  
 
Subanalysis related to antifibrotic administration 
Analyses in patients who had never received antifibrotic medication but fulfilled 
drug trial entry criteria (DLco≥30% predicted), in the discovery (n=128) and 
validation cohorts (n=72) are demonstrated in Figure 2G-I, and Figure 3A-C. Upper 
zone VRS variables were the strongest predictors of FVC decline (Figure 2G and 3A), 
10% FVC decline/death at 12 months (Figure 2H and 3B) and survival (Figure 2I and 
3C). Upper and midzone VRS variables outperformed functional indices for all three 
study outcome measures. Results were maintained when patients were stratified 
based on the median cohort DLco of 40.15% predicted - below median DLco: Figures 
3B, E and H; above median DLco: Figures 3C, F and I.  
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In patients with a DLco≥30% predicted who had received antifibrotics (n=32 in the 
discovery cohort, n=127 in the validation cohort), upper and midzone VRS variables 
were the strongest predictors of FVC decline (Supplementary Figure 2D) and 10% 
FVC decline/death at 12 months (Supplementary Figure 2E) and outperformed DLco 
and CPI. UZ VRS subdivisions were similar to DLco and CPI in their ability to predict 
survival (Supplementary Figure 2F). 
 
C-Index analyses 
The relative strength of adjusted models predicting the combined endpoint of 10% 
FVC decline/death at 12 months were compared using the C-index for models 
containing CALIPER VRS subdivision scores, functional indices and visual CT variables. 
All models were adjusted for patient age, gender, smoking status and reconstruction 
algorithm in patients with a DLco≥30% predicted who had never received 
antifibrotics (n=175). Models were examined separately in the combined cohorts, 
the discovery cohort and the validation cohort (Supplementary Table 2). Models in 
the combined cohorts, containing CALIPER VRS subdivisions outperformed models 
containing functional indices in predicting the combined endpoint. 
 
When adjusted Cox mortality models were compared using the C-index, models 
containing CALIPER VRS subdivisions demonstrated higher C-indices than models 
containing FVC, DLco and CPI in the combined cohort (Supplementary Table 2). The 
addition of an upper or midzone VRS subdivision score to a model containing a 
functional index increased, to a modest degree, the model C-index in all cases 
(Supplementary Table 3).  
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Patients with severe disease 
When patients with severe disease (DLco<30% predicted) were evaluated (n=168), 
CPI and DLco were clearly shown to be the strongest predictors of survival 
(Supplementary Figure 3C). Results were maintained on subanalysis of patients who 
received antifibrotic medication (n=29)[Supplementary Figure 2C]. No variables 
strongly predicted FVC decline or a 10% FVC decline/death at 12 months in all study 
patients with a DLco<30% predicted (Supplementary Figure 3A and B) or when those 
receiving antifibrotic medication were subanalysed (n=27)[Supplementary Figure 2A 
and B].  
 
When patients with a DLco<30% predicted, who had never received antifibrotics 
were subanalysed (n=139), lower zone VRS subdivisions were better predictors of 
FVC decline than DLco or CPI (Supplementary Figure 3D). Upper zone VRS 
subdivisions demonstrated stronger relationships with 10% FVC decline/death at 12 
months and survival than DLco or CPI in patients with severe disease that were not 
exposed to antifibrotics (Supplementary Figure 3E and F). 
 
Cohort enrichment using CALIPER VRS thresholds 
The primary aim of or study was to see whether computer quantitation of CT 
imaging could have a role in cohort enrichment of IPF drug trials. In a final analysis, 
we aimed to calculate potential savings to an IPF drug trial that would result from 
cohort enrichment of a study population using various CALIPER total VRS thresholds 
(Table 1). Using IPF patients with a DLco≥30% predicted, we modelled sample size 
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savings for a drug with three potential effect sizes on FVC decline (25%, 40% and 
50% reduction in FVC decline). At each drug effect size we looked at cohort 
enrichment using three CALIPER VRS thresholds (representing the total VRS score 
throughout the entire lungs) corresponding to 70% (CVRS=3.7% of the lung), 50% 
(CVRS =4.4% of the lung) and 30% (CVRS =5.1% of the lung) of the original IPF study 
population.  
 
As shown in Table 1, restricting a clinical trial cohort to IPF patients with a CVRS of 
4.4% of the lung or greater, it would be possible to reduce sample size by 26% to 
identify the same drug treatment effect size. Importantly, half of all IPF patients 
studied were included in the CVRS threshold of >4.4% of the lung. The model C-index 
for the CAL VRS threshold of 4.4% in the discovery cohort of patients with a 
DLco≥30% predicted, not on antifibrotics (n=128) was 0.67 for survival and 0.73 for 
the combined endpoint of 10% FVC decline/death in 12 months. The equivalent C-
indices in the validation cohort (n=72, following exclusion of patients on antifibrotics 
and those with a DLco<30% predicted) were 0.56 for survival and 0.64 for the 
combined endpoint.  
 
As a final analysis, to exclude the possibility that the CVRS threshold of 4.4% was 
identifying patients that were likely to progress regardless of any medical 
intervention, we examined the effect of antifibrotic medication in all study patients 
with a DLco≥30% predicted, with a VRS >4.4% (n=190). Our results demonstrated 
that antifibrotic use in this subpopulation increased life expectancy (Mortality 
analysis: OR=0.437, 95%CI 0.298 - 0.641; Z= -4.239, p=2.25x10-5; 10% FVC 
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decline/death in 12 months: OR= 0.246, 95%CI 0.122 - 0.498; Z= -3.89, p=9.73x10-5) 
and reduced FVC decline (fitted between group difference in annual relative FVC 
change: 3.36% ; 95%CI 0.39% - 6.5%; T=2.22, p=0.027). Accordingly, it would seem 
that patients being selected using CALIPER VRS thresholds are patients that would 
respond to antifibrotic medication and represent a good population with which to 
enrich an IPF drug trial. 
 
DISCUSSION 
Our study has demonstrated, across two cohorts of patients with IPF, that computer-
derived CT variables, particularly the CALIPER vessel-related structures, predict two 
separate disease end-points, survival and FVC decline at 12 months and demonstrate 
an enhanced effect size in IPF patients with less extensive disease. Most importantly, 
VRS scores can be utilized in cohort enrichment of an IPF population. Patients 
selected using a CALIPER total VRS threshold of over 4.4% were shown to reduce an 
IPF drug trial sample size by 26%, and were shown to have an increased life-
expectancy and reduced rate of FVC decline when receiving antifibrotic medication 
compared to patients not receiving antifibrotics. 
 
Existing computer algorithms that have approached the analysis of CT imaging in IPF 
have done so by characterising and quantifying the standard library of CT 
parenchymal patterns, recognised visually by radiologists for over 20 years(28, 38-
40). The advent of volumetric CT datasets however has allowed three-dimensional 
structural information within the lungs to be analysed across several hundred CT 
images. Furthermore, features such as the pulmonary vessel-related structures, that 
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have not been associated with prognostication outside the ambit of CALIPER studies, 
can now be quantified.  
 
The VRS measure predominantly quantifies pulmonary arteries and veins but also 
captures connected tubular structures mainly representing adjoining regions of 
fibrosis. Our results regarding the utility of CALIPER-defined VRS quantitation as a 
prognostic tool, may represent the first example of a non-traditional CT parameter, 
derived by a computer and therefore having no inherent measurement variation 
constraints, that strongly predicts mortality in IPF. As computer tools evolve and 
supervised machine learning progresses, the scope for identifying novel prognostic 
features that have been overlooked using visual analysis can only increase.  
 
Pulmonary function tests, specifically DLco and CPI were the strongest predictors of 
survival in IPF patients with severe disease (DLco<30% predicted). Without the 
benefit of comprehensive right heart catheter measurements however, the 
possibility that a major determinant of mortality in patients with extensive disease 
reflects pulmonary hypertension can only remain speculative. The prognostic value 
of functional tests however reduced in strength in patients with less extensive 
disease. Similarly, the GAP index did not strongly predict the likelihood of future FVC 
decline in patients with less extensive disease, confirming a previous report(41).  
 
Whilst traction bronchiectasis has been recognised as a predictor of mortality in 
previous reports in IPF(42, 43), our results are the first proof of their utility in 
predicting FVC decline. The strength with which a relatively simple visual traction 
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bronchiectasis score predicted FVC decline suggests that the development of an 
automated measure of traction bronchiectasis would be a desirable tool for further 
prognostic analyses in IPF.  
 
VRS in the upper zones were amongst the strongest predictors of mortality in most 
analyses whilst no powerful mortality signal was obtained from VRS in the lower lung 
zones, regardless of the severity of underlying fibrosis. The results argue for the 
selective evaluation of VRS in discrete lung subunits. 
 
The potential utility of CALIPER as a cohort enrichment tool could help reduce the 
prohibitive cost of modern drug trials in IPF. With patients in the control arms of new 
trials receiving anti-fibrotics and therefore demonstrating a slower decline in FVC 
when compared to the earlier placebo-controlled Nintedanib(16) and 
Pirfednidone(17) trials, the recognition of a drug treatment effect from a novel agent 
will require larger sample sizes in a trial and potentially longer patient follow up. 
However, the use of CALIPER total VRS scores may allow selective recruitment of IPF 
patients that are likely to demonstrate more rapid FVC decline. Accordingly, savings 
in trial size and follow up and therefore cost are likely.  
 
One of the main limitations of computer analysis of CT imaging relates to the 
requirement of non-contrast volumetric imaging acquired using appropriate 
reconstruction algorithms. In the current study, most of the CT scans were 
performed using edge-enhancing algorithms that can result in the misclassification 
of honeycombing, reticulation or even ground glass opacities. It was to avoid such 
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misclassification, that the most severely edge enhanced algorithm (Siemens B80) 
was not evaluated in our study.  
 
For institution of CALIPER CT analysis as a cohort enrichment tool for a drug trial, 
several preparatory steps would be necessary at the various clinical trial centres. 
Firstly, scrupulous attention would need to be paid to the quality of the CT scan 
acquired. An optimal full inspiratory breath at total lung capacity is essential and 
could be aided with a form of spirometric gating. The desired scanner algorithms 
used to reconstruct the CT would be clearly specified to avoid severely edge-
enhancing algorithms.  
 
Once acquired, the anonymized volumetric, non-contrast digital imaging and 
communications in medicine (DICOM) axial CT files would be electronically sent by a 
CT technician to a central processing hub, for example at the Biomedical Imaging 
Resource, Mayo Clinic, Rochester, Minnesota, USA. Some pre-processing of CT data 
might be necessary prior to computer analysis to reduce image noise, and though 
this step can be inadvertently overlooked, its importance, to ensure optimal 
parenchymal characterisation, cannot be overstated. Once ready for analysis, 
CALIPER processing of an entire CT examination takes less than one minute, though 
is accompanied by careful quality control of segmentation accuracy. The anonymized 
data-files can then be electronically sent to a trial coordinator the same working day. 
In our study, CALIPER VRS quantitation remained predictive of mortality across a 
spectrum of CT algorithms in the validation cohort suggesting that CALIPER VRS 
measures may have a role in future multicentred studies. 
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There were limitations to the current study. The measurement of VRS by CALIPER 
predominantly included pulmonary arteries and veins, but in patients with extensive 
fibrosis, there is invariably a degree of capture of reticular densities and 
peribronchial fibrosis. It therefore remains unclear just how much the associated 
perivascular fibrosis may contribute to overall variable strength. Importantly, the 
VRS scores strongly predicted survival when measured in the upper lung zones, 
where fibrosis is least extensive in IPF, and retained utility across independent 
patient populations and a range of reconstruction algorithms suggesting a 
robustness to the measure. Lastly, whilst the time intervals of FVC measurement in 
our study were not standardised in line with current drug trial protocols, our study 
has the advantage of a longer follow up than is usually possible in a drug trial setting. 
 
In conclusion, our study has shown that in IPF, computer analysis of CT imaging, in 
particular, quantitation of pulmonary vessel-related structures can strongly predict 
survival and likelihood of FVC decline with effects enhanced over functional indices 
in patients with less extensive disease. Importantly, CALIPER VRS scores can 
selectively identify IPF patients who will reach drug trial endpoints and respond to 
antifibrotic medication. CALIPER VRS scores may therefore have a major role in drug 
trial cohort enrichment reducing the prohibitive costs of current IPF trials.   
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Supplementary Appendix: 
Pulmonary Function Protocol 
Pulmonary function tests (PFT) were analysed if performed within 3 months of the 
corresponding CT scan according to established protocols (44). Spirometry (Jaeger 
Master screen PFT, Carefusion Ltd., Warwick, UK and Houten, NL), plethysmographic 
lung volumes (Jaeger Master screen Body, Carefusion Ltd., Warwick, UK and Houten, 
NL), and diffusion capacity for carbon monoxide (Jaeger Master screen PFT, 
Carefusion Ltd., Warwick. UK and Houten, NL) Parameters assessed: forced 
expiratory volume in one second (FEV1), forced vital capacity (FVC) and single breath 
carbon monoxide diffusing capacity corrected for hemoglobin concentration (DLco). 
The composite physiologic index (CPI) was calculated using the formula: 91·0 - (0·65 
x % predicted DLco) - (0·53 x % predicted FVC) + (0·34 x % predicted FEV1). (45) The 
gender, age, physiology (GAP) score and GAP index were also calculated for both 
cohorts by summing threshold ranges of patient age, gender, FVC and DLco(46). 
 
CT Protocol 
CT scans at the Royal Brompton Hospital were obtained using a 64-slice multiple 
detector CT scanner (Somatom Sensation 64; Siemens, Erlangen, Germany) or a 4-
slice multiple-detector CT scanner (Siemens Volume Zoom; Siemens, Erlangen, 
Germany). All images were reconstructed using a high spatial frequency, B70 kernel 
(Siemens, Munich, Germany). CT scans at the St. Antonius Hospital, Nieuwegein, 
were obtained using a 64-slice multiple detector CT scanner (Phillips Brilliance 64; 
Cleveland, Ohio, USA) or a 256-slice multiple-detector iCT scanner (Phillips, 
Cleveland, Ohio, USA). All images were reconstructed using C, EC, L or YC kernels 
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(Phillips, Cleveland, Ohio, USA). 
 
All patients were scanned from lung apices to bases, at full inspiration, using a peak 
voltage of 120 kVp with tube current modulation (range, 30 to 140 mA). Images of 
0.5-1mm thickness were viewed at window settings optimized for the assessment of 
the lung parenchyma (width 1500 HU; level -500 HU). 
 
Visual CT scoring 
Each CT was independently evaluated by two radiologists (AN and SLW of 5 and 7 
years thoracic imaging experience or GC and JB of 3 and 4 years experience), blinded 
to all clinical information. CT scoring of the study population commenced after 
evaluation of a training dataset of 15 cases by both pairs of radiologists to identify 
and resolve underlying inherent biases in the characterisation of CT patterns. Results 
that were discrepant by more than two standard deviations for both scorer pairs 
were consensed by a third scorer (JJ) who has access to the original visual CT scores. 
 
CTs were scored on a lobar basis using a continuous scale. The total interstitial lung 
disease (ILD) extent was estimated to the nearest 5% and subclassified into 4 
patterns: reticular pattern, ground-glass opacification, honeycombing, and 
consolidation, using definitions from the Fleischner Society glossary of terms for 
thoracic imaging(47). To derive a lobar percentage for each parenchymal pattern, 
the total lobar ILD extent was multiplied by individual lobar parenchymal pattern 
extents and divided by 100. The percentage (to the nearest 5%) of each lobe that 
contained emphysema was also recorded. For each radiologist, the individual lobar 
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percentages of each parenchymal pattern were summed and divided by 6 to create 
an averaged lobar score per pattern, per scorer per case. 
 
Traction bronchiectasis, as defined in the Fleischner Society glossary of terms(47), 
was assigned with two categorical scores. The first “severity” score took into account 
the average degree of airway dilatation within areas of fibrosis as well as the extent 
of dilatation throughout the lobe and was given an overall score of: none=0, mild=1, 
moderate=2, severe=3 in a 19-point scale (score range=0-18). The second “extent” 
score summed the numbers of segments of the lung (to a maximum of 3 segments 
per lobe) containing traction bronchiectasis resulting in a 17-point scale (score range 
=0-16 as the middle lobes contain only two segments). 
 
CALIPER CT evaluation 
Data processing 
Data processing steps have been previously described(27, 48, 49). In reconstruction 
algorithms utilizing an edge-enhancing algorithm (Siemens B70, Phillips L and YC), a 
median filter was applied to 3x3x1 voxel volumes. The Siemens B80 algorithm was 
markedly edge-enhancing and resulted in misclassification of parenchymal features 
such as honeycombing. As a result, CT imaging reconstructed with the Siemens B80 
algorithm (n=6) were excluded from the study.  
 
After the median filter pre-processing step for the other edge-enhancing CT 
algorithms, the lungs were extracted from the surrounding thoracic structures and 
then segmented into upper, middle, and lower lung zones using the carina as a 
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landmark. Lung segmentation was performed with an adaptive density-based 
morphologic approach,(50) whereas airway segmentation involved iterative 3-
dimensional region growing, density thresholding (thresholds including 950HU and 
960 HU), and connected components analysis. Parenchymal tissue type classification 
was applied to 15x15x15 voxel volume units using texture analysis, computer vision-
based image understanding of volumetric histogram signature mapping features, 
and 3-dimensional morphology(27). 
 
Pulmonary vessel extraction was achieved using an optimised multiscale tubular 
structure enhancement filter based on the eigenvalues of the Hessian matrix. More 
precisely, the second-order derivatives that occurred in the regions that surrounded 
each pulmonary voxel were calculated and formed the Hessian matrix. The 
eigenvalues of this Hessian matrix were then computed and used to determine the 
likelihood that an underlying voxel was connected to a dense tubular structure and 
therefore represented a vessel or vessel-related tubular structure (27, 51). The 
pulmonary VRS score (CALIPER VRS) excluded vessels at the lung hilum and 
expressed the VRS as a percentage of the total lung volume. 
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CVRS Threshold Setting A (25% effect) Setting B (40% effect) Setting C (50% effect) 
(Percentage of 
population) 
N (size) Size diff (%) N (size) Size diff (%) N (size) Size diff (%) 
0 (100) 2480 0 970 0 622 0 
3.7 (70) 2432 48 (2) 952 18 (2) 610 12 (2) 
4.4 (50) 1824 656 (26) 714 256 (26) 458 164 (26) 
5.1 (30) 1790 690 (28) 702 268 (28) 450 172 (28) 
 
Table 1. Impact of cohort enriching an IPF drug trial study population by analysing 
baseline CT imaging and stratifying patients according to various thresholds of 
CALIPER total vessel-related structures (CVRS). Statistical modelling was performed 
to calculate the number of patients that would be required in a study to identify a 
drug effect of 25%, 40% and 50% reductions in forced vital capacity (FVC) decline. 
The number of patients in the unenriched cohort are demonstrated (CVRS threshold 
of 0) and the savings in drug trial sample size when using three CVRS thresholds 
(3.7%, 4.4%, 5.1% of the lung equating to 70%, 50% and 30% of the study population 
respectively) are expressed as a number and percentage.  
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Figure 1. Colour overlay CT images demonstrating CALIPER vessel-related structures 
(VRS) of different sizes in the upper and middle lung zones in three IPF patients with 
varying degrees of disease severity. A 78-year-old male ex-smoker (diffusion capacity 
for carbon monoxide (DLco)=69.7% predicted) demonstrates mild reticulation at the 
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anterior and posterior aspects of the lungs (A+B). A 56-year-old female ex-smoker 
(DLco=57.1% predicted) demonstrates coarse reticulation most marked in the apical 
segments of the lower lobes bilaterally (C+D). A 68-year-old male ex-smoker 
(DLco=27.5% predicted) has more extensive reticulation in the lung periphery and at 
the lung bases. As fibrosis extent increases, so too does the VRS score within the 
lungs. VRS size key: red=<5mm2, green=5-10mm2, yellow=10-15mm2, dark blue=15-
20mm2, light blue=>20mm2. 
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Figure 2. Scatterplots demonstrating -log10 p-values for variables (various computer-
derived (CALIPER), visual CT-derived and pulmonary function indices) in the 
discovery cohort (x-axis) and validation cohort (y-axis). Horizontal and vertical dotted 
lines represent the Li and Ji corrected cutoff for statistical significance. Graphs A-C 
represent all subjects, graphs D-F represent patients with a DLco≥30% predicted, 
graphs G-I represent patients with a DLco≥30% predicted who were not exposed to 
antifibrotic medication. The first column of graphs (A,D,G) represent variables 
predicting FVC decline. The second column of graphs (B,E,H) represent variables 
predicting a 10% FVC decline or death within 12 months. The third column of graphs 
(C,F,I) represent variables predicting survival. In graph C, to allow visualization of all 
the points on the graph, values that were infinite (due to a p-value of 0) were set to 
20. DLco=diffusing capacity for carbon monoxide, CPI=composite physiologic index, 
TxBx=traction bronchiectasis (extent and severity), CFibrosis=CALIPER fibrosis extent, 
CAL VRS=CALIPER vessel-related structure, UZ=upper zone, MZ=middle zone, UZ 
VRS=upper zone vessel-related structure. The pulmonary vessel-related structure 
score was subdivided according to structure cross-sectional area (<5mm2, 5-10 mm2, 
10-15 mm2, 15-20 mm2, >20 mm2). 
 
Figure 3. Graphs A-C demonstrate -log10 p-values for variables (various computer-
derived (CALIPER), visual CT-derived, echocardiography-derived and pulmonary 
function indices) in all study patients (discovery and validation cohorts) with a DLco 
≥30% predicted who were not exposed to antifibrotic medication. The patients were 
stratified with regard to disease severity, based on the median DLco value for the 
combined cohort (40.15% predicted), with results for patients below the median 
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DLco shown in graphs (D-F) and patients above the median DLco shown in graphs (G-
I). Graphs A,D and G represent variables predicting FVC decline, graphs B,E and H 
represent variables predicting a 10% FVC decline or death within 12 months, and 
graphs C,F and I represent variables predicting survival. DLco=diffusing capacity for 
carbon monoxide, CPI=composite physiologic index, CVRS=CALIPER vessel-related 
structure, UZ=upper zone, MZ=middle zone, LZ=lower zone, UZVRS=upper zone 
vessel-related structure, MZVRS=middle zone vessel-related structure, LZVRS=lower 
zone vessel-related structure, The pulmonary vessel-related structure score was 
subdivided according to structure cross-sectional area (<5mm2, 5-10 mm2, 10-15 
mm2, 15-20 mm2, >20 mm2). 
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Supplementary Materials: 
 
Population Variable Discovery Cohort 
(n=247 unless 
stated) 
Validation Cohort 
(n=284 unless 
stated) 
Cohort 
Comparison  Units are percentage 
unless stated 
All IPF patients Median Age (years) 67 69   0.14* 
Male/female (ratio) 192/55  225/59    0.68* 
Survival (alive/dead) 63/184 93/191   0.07* 
FVC % predicted  69.1 ± 20.1 (242) 74.2 ± 19.5 (283)   0.003 
DLco % predicted 36.3 ± 12.9  39.1 ± 14.4    0.02 
CPI 55.2 ± 11.5 (242) 52.8 ± 12.6 (283)   0.02 
CALIPER ILD extent  25.4 ± 17.0 23.5 ± 16.3   0.19 
CALIPER VRS  5.0 ± 1.6 5.3 ± 1.7   0.10 
IPF patients with 
a DLco<30% 
predicted 
FVC % predicted  75.3 ± 18.7 (159) 79.0 ± 17.8 (199)   0.06 
DLco % predicted 43.0 ± 10.2 (163) 45.8 ± 11.4 (200)   0.01 
CPI 49.5 ± 9.3  (159) 47.4 ± 10.4 (199) <0.05 
CALIPER ILD extent  19.8 ± 13.2 (163) 18.4 ± 13.1 (200)   0.32 
CALIPER VRS  4.5 ± 1.3     (163) 4.7 ± 1.5     (200)   0.08 
 
Supplementary Table 1. Comparison of patient characteristics in both IPF cohorts. 
Key characteristics of all IPF patients in the discovery and validation cohorts with a 
subanalysis in patients with a DLco≥30% predicted. Data represent median values for 
patient age and mean values with standard deviations for CALIPER and lung function 
variables. Statistically significant differences between the two groups were 
calculated using the Chi-Square test for categorical independent variables (*) and the 
T test for continuous variables. FVC = forced vital capacity, DLco=diffusing capacity 
for carbon monoxide, CPI=composite physiologic index, ILD=interstitial lung disease, 
VRS= vessel-related structure. 
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Supplementary Table 2. C-index values for CALIPER, functional and visual CT 
variables predicting survival or a combined endpoint of a 10% FVC decline/death 
within 12 months, in all study patients with a DLco≥30% not receiving antifibrotic 
Variable 
Combined Cohort Discovery Cohort Validation Cohort 
Survival 
10% FVC 
decline or 
death in 
12mths Survival 
10% FVC 
decline or 
death in 
12mths Survival 
10% FVC 
decline or 
death in 
12mths 
CAL VRS 0.68 0.73 0.69 0.75 0.63 0.67 
UZ VRS 0.67 0.76 0.69 0.77 0.61 0.69 
UZ (5-10mm) 0.67 0.75 0.69 0.76 0.58 0.69 
UZ (10-15mm) 0.67 0.76 0.67 0.76 0.60 0.72 
MZ VRS 0.67 0.70 0.68 0.72 0.63 0.64 
UZ (>20mm) 0.66 0.74 0.67 0.75 0.62 0.71 
MZ (15-20mm) 0.66 0.70 0.67 0.72 0.62 0.63 
MZ (10-15mm) 0.66 0.70 0.67 0.70 0.61 0.66 
MZ (>20mm) 0.66 0.69 0.68 0.73 0.63 0.65 
UZ (<5mm) 0.65 0.73 0.68 0.75 0.54 0.57 
CFibrosis 0.65 0.73 0.65 0.70 0.64 0.73 
UZ (15-20mm) 0.64 0.75 0.65 0.76 0.59 0.69 
CILD 0.64 0.69 0.64 0.70 0.57 0.64 
MZ (5-10mm) 0.64 0.68 0.65 0.69 0.58 0.61 
CPI 0.64 0.68 0.63 0.66 0.66 0.62 
GAPindex 0.63 0.68 0.64 0.62 0.64 0.76 
FVC 0.63 0.68 0.63 0.66 0.61 0.63 
MZ (<5mm) 0.62 0.65 0.63 0.64 0.56 0.53 
LZ (>20mm) 0.62 0.64 0.60 0.59 0.60 0.72 
LZ (15-20mm) 0.61 0.65 0.60 0.65 0.58 0.65 
DLco 0.61 0.65 0.59 0.57 0.65 0.62 
LZ VRS 0.61 0.64 0.57 0.59 0.59 0.63 
TxBx (extent) 0.60 0.65 0.61 0.68 0.57 0.62 
LZ (10-15mm) 0.60 0.64 0.58 0.60 0.57 0.59 
TxBx (severity) 0.60 0.64 0.57 0.61 0.60 0.67 
VILD 0.60 0.63 0.60 0.61 0.57 0.55 
VFibrosis 0.60 0.62 0.58 0.57 0.56 0.57 
LZ (5-10mm) 0.56 0.60 0.54 0.58 0.52 0.53 
VHC 0.55 0.61 0.58 0.52 0.48 0.66 
LZ (<5mm) 0.53 0.60 0.51 0.51 0.48 0.48 
CHC 0.49 0.60 0.49 0.51 0.45 0.67 
GAPscore 0.48 0.59 0.56 0.52 0.33 0.41 
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medication. Results are separately shown for the combined endpoint in the 
combined population (n=175), the discovery cohort (n=118) and the validation 
cohort (n=57) and mortality analyses in the combined population (n=200), the 
discovery cohort (n=128) and the validation cohort (n=72). All models were adjusted 
for patient age, gender, smoking status (never versus ever) and CT reconstruction 
algorithm. FVC = forced vital capacity, DLco=diffusing capacity for carbon monoxide, 
CPI=composite physiologic index, GAP=gender, age and physiology (score and index), 
CILD=CALIPER interstitial lung disease extent, CFibrosis=CALIPER fibrosis extent, 
CHC=CALIPER honeycombing extent, CAL VRS=CALIPER vessel-related structure, 
UZ=upper zone, MZ=middle zone, LZ=lower zone, UZVRS=upper zone vessel-related 
structure, MZVRS=middle zone vessel-related structure, LZVRS=lower zone vessel-
related structure, VILD=Visual interstitial lung disease extent, VFibrosis=Visual 
fibrosis extent, VHC=Visual honeycombing extent, TxBx=traction bronchiectasis. The 
pulmonary vessel-related structure score was subdivided according to structure 
cross-sectional area (<5mm2, 5-10 mm2, 10-15 mm2, 15-20 mm2, >20 mm2). 
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FVC 
 
DLco 
 
CPI 
 
UZ VRS 0.044 0.065 0.039 
MZ VRS 0.045 0.054 0.032 
LZ VRS 0.011 0.011 0.003 
UZ (<5mm) 0.019 0.045 0.025 
UZ (5-10mm) 0.037 0.059 0.032 
UZ (10-15mm) 0.036 0.058 0.031 
UZ (15-20mm) 0.021 0.043 0.020 
UZ (>20mm) 0.035 0.058 0.032 
MZ (<5mm) 0.017 0.022 0.008 
MZ (5-10mm) 0.024 0.033 0.016 
MZ (10-15mm) 0.038 0.050 0.026 
MZ (15-20mm) 0.037 0.052 0.028 
MZ (>20mm) 0.039 0.051 0.035 
LZ (<5mm) -0.006 -0.004 0.003 
LZ (5-10mm) -0.004 -0.002 -0.001 
LZ (10-15mm) 0.008 0.006 0.001 
LZ (15-20mm) 0.009 0.013 0.007 
LZ (>20mm) 0.024 0.030 0.018 
CAL VRS 0.051 0.069 0.044 
 
Supplementary Table 3. Change in C-index values when CALIPER VRS variables were 
added to adjusted survival models containing functional indices (forced vital capacity 
(FVC); diffusing capacity for carbon monoxide (DLco) and composite physiologic 
index (CPI). All study patients with a DLco≥30% predicted not receiving antifibrotic 
medication were examined (n=200) and all models were adjusted for patient age, 
gender, smoking status (never versus ever) and CT reconstruction algorithm. A 
positive value indicates that the addition of a VRS variable improves the model. 
VILD=Visual interstitial lung disease extent, VFibrosis=Visual fibrosis extent, 
VHC=Visual honeycombing extent, CAL VRS=CALIPER vessel-related structure, 
UZ=upper zone, MZ=middle zone, LZ=lower zone, UZVRS=upper zone vessel-related 
structure, MZVRS=middle zone vessel-related structure, LZVRS=lower zone vessel-
related structure. The pulmonary vessel-related structure score was subdivided 
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according to structure cross-sectional area (<5mm2, 5-10 mm2, 10-15 mm2, 15-20 
mm2, >20 mm2).  
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Supplementary Figure 1. Kaplan Meier survival curves for IPF patients in the 
discovery (a) and validation (b) cohorts and for those patients in each cohort with a 
DLco≥30% predicted. All IPF patients in discovery cohort: blue, n=247, restricted 
median survival=27.6±1.8; validation cohort: green, n=284, restricted median 
survival=29.7±2.9. Log rank test p=0.52. IPF patients with a DLco≥30% predicted in 
discovery cohort: blue, n=163, restricted median survival=42.2±2.6; validation 
cohort: green, n=200, restricted median survival=39.7±3.0. Log rank test p=0.98 
 
Supplementary Figure 2. Graphs A-C demonstrate -log10 p-values for CALIPER vessel-
related structure subdivisions, composite physiologic index (CPI) and diffusing 
capacity for carbon monoxide (DLco), in all study patients with a DLco<30% 
predicted (discovery and validation cohorts) that received antifibrotic medication 
(n=29). Graphs D-F represent similar analyses in study patients with a DLco≥30% 
predicted, who received antifibrotic medication (n=159). Graphs A and D represent 
variables predicting FVC decline, graphs B and E represent variables predicting a 10% 
FVC decline or death within 12 months, and graphs C and F represent variables 
predicting survival.  DLco=diffusing capacity for carbon monoxide, CPI=composite 
physiologic index, CAL VRS=CALIPER vessel-related structure, UZ=upper zone, 
MZ=middle zone, LZ=lower zone, UZVRS=upper zone vessel-related structure, 
MZVRS=middle zone vessel-related structure, LZVRS=lower zone vessel-related 
structure. The pulmonary vessel-related structure score was subdivided according to 
structure cross-sectional area (<5mm2, 5-10 mm2, 10-15 mm2, 15-20 mm2, >20 
mm2). 
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Supplementary Figure 3. Graphs A-C demonstrate -log10 p-values for CALIPER vessel-
related structure subdivisions, composite physiologic index (CPI) and diffusing 
capacity for carbon monoxide (DLco), in all study patients (discovery and validation 
cohorts) with a DLco<30% predicted (n=168). Graphs D-F represent a subanalysis in 
study patients with a DLco<30% predicted, who were not exposed to antifibrotic 
medication (n=139). Graphs A and D represent variables predicting FVC decline, 
graphs B and E represent variables predicting a 10% FVC decline or death within 12 
months, and graphs C and F represent variables predicting survival. DLco=diffusing 
capacity for carbon monoxide, CPI=composite physiologic index, CAL VRS=CALIPER 
vessel-related structure, UZ=upper zone, MZ=middle zone, LZ=lower zone, 
UZVRS=upper zone vessel-related structure, MZVRS=middle zone vessel-related 
structure, LZVRS=lower zone vessel-related structure. The pulmonary vessel-related 
structure score was subdivided according to structure cross-sectional area (<5mm2, 
5-10 mm2, 10-15 mm2, 15-20 mm2, >20 mm2). 
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